The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; MSD; Pfizer; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer; Roche/Genentech; Takeda
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Oscar Juan-Vidal
No Relationships to Disclose
 
Giannis Socrates Mountzios
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/Greece; BMS GmbH & Co. KG; MSD; Novartis; Roche; Takeda
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Demo Pharmaceutical; Ipsen; MSD; Novartis; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Niels Reinmuth
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Sanofi Aventis GmbH; Takeda
Travel, Accommodations, Expenses - Janssen
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Vipul M. Patel
No Relationships to Disclose
 
Takayuki Takahama
Speakers' Bureau - AstraZeneca Japan; Chugai Pharmaceutical Co Ltd.; MSD K.K; Roche Diagnostics Solutions
Research Funding - Pfizer; Takeda
 
Scott Peter Owen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; Novocure; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Roche Canada; Takeda
 
Douglas Reznick
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences; Merck
Honoraria - AstraZeneca; Guardant Health
Speakers' Bureau - AstraZeneca; Guardant Health
 
Firas Benyamine Badin
Honoraria - Amgen; Bristol-Myers Squibb; EMD Serono; Guardant Health; Incyte; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Natera; Pfizer; Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; EMD Serono; Guardant Health; Incyte; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Natera; Pfizer; Regeneron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; EMD Serono; Guardant Health; Incyte; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Merck; Natera; Pfizer; Regeneron
 
Irfan Cicin
Consulting or Advisory Role - Abbvie (Inst); Abdi Ibrahim (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Gen (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Nobelpharma (Inst); Novartis/Ipsen (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst); Takeda (Inst); Teva
Speakers' Bureau - Abdi Ibrahim (Inst); Astellas Pharma; Bristol-Myers Squibb (Inst); Gen (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Teva (Inst)
 
Sabeen Fatima Mekan
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences
 
Riddhi Patel
No Relationships to Disclose
 
Eric Zhang
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Divyadeep Karumanchi
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck